XML 96 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Major Customers, Partnerships and Strategic Alliances (Tables)

12 Months Ended

Dec. 31, 2019

Kite Pharma, Inc. ("Kite")

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues recognized under agreement

Revenues recognized under the agreement were as follows (in thousands):

			Year Ended December 31,
			2019						2018
Revenue related to Kite agreement:
Recognition of license and stand-ready fee			$	24,977					$	18,545
Research services			9,373						6,972
Total			$	34,350					$	25,517

Pfizer SB-525

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues recognized under agreement

Revenues recognized under the agreement were as follows (in thousands):

			Year Ended December 31,
			2019						2018						2017
Revenue related to Pfizer SB-525 agreement:
Recognition of upfront fee and research services			$	15,697					$	37,810					$	17,008
Milestone achievement			23,662						—						—
Total			$	39,359					$	37,810					$	17,008

Pfizer C9ORF72

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues recognized under agreement

Revenues recognized under the agreement were as follows (in thousands):

			Year Ended December 31,
			2019						2018						2017
Recognition of upfront fee related to Pfizer C9ORF72 agreement			$	1,827					$	2,188					$	—

Sanofi

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues recognized under agreement

Revenues recognized under the agreement were as follows (in thousands):

			Year Ended December 31,
			2019						2018						2017
Revenue related to Sanofi agreement:
Recognition of upfront fee			$	3,494					$	4,013					$	1,769
Research services			6,367						9,503						10,489
Milestone achievement			12,819						—						—
Total			$	22,680					$	13,516					$	12,258

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: